Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$10.78 USD
-0.27 (-2.44%)
Updated May 23, 2024 04:00 PM ET
After-Market: $10.78 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
Maravai LifeSciences Holdings, Inc. [MRVI]
Reports for Purchase
Showing records 1 - 20 ( 72 total )
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for MRVI 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
3Q Light, Positive EBITDA, LT Goal Reiterated
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Investor Day - Post-Pandemic Portfolio Provides More Ways to Win
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
2Q23 - FY23 Finally De-Risked? Downgrade to Sector Weight
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Chatter of Buyer (Again) and Comparables
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Risk Factors for Life Science May Be de Minimis
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
4Q22 in Line and FY23 Guidance Sets the Stage for LT Potential
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
ChatGPT / Generative AI Creating a Significant Opportunity for NVDA, but Challenges Exist
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Triangulating mRNA Potential, Revised Model, More Clarity
Provider: KeyBanc Capital Markets
Analyst: Research Department